Back

Long-Term outcome of ventricular tachycardia catheter ablation in ischemic heart disease patients using a high-density mapping substrate-based approach: a prospective cohort study

23 April 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: ePoster session Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2021

About the speaker

Photo
Doctor Pedro Silverio Antonio

University of Lisbon, Lisbon (Portugal)

286 More presentations in this session

Presentation thumbnail
Non-valvular atrial fibrillation recurrence after sinus rhythm restoring at different follow-up periods: phenotype-genotype high-risk groups, considering rs10465885 polymorphism in connexin-40 gene
Doctor T. Mikhalieva (Kyiv, UA)
Abstract Slides
Presentation thumbnail
Atrial fibrillation substrate mapping with decrement evoked potential mapping.
Doctor O. Salvador (Parla, ES)
Abstract Slides
Presentation thumbnail
Atrial tissue characterization by cardiac magnetic resonance and high-density mapping in patients with atrial fibrillation
Miss R. Adelino Recasens (Barcelona, ES)
Abstract Slides
Presentation thumbnail
Proarrhythmic atrial structural and molecular remodeling with advancing age. Implications for post-coronary artery bypass grafting atrial fibrillation occurrence.
Doctor R. SERBAN (Targu Mures, RO)
Abstract Slides
Presentation thumbnail
Find me if you can: lessons learned using the novel cartofinder algorithm in a routine workflow for catheter ablation of atrial fibrillation
Doctor C. Sohns (Bad Oeynhausen, DE)
Abstract Slides

Access the full session

Session thumbnail
ePoster session

The Event

Event poster

EHRA 2021

23 April - 25 April 2021
You may be interested in
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources